SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (20955)4/21/1999 9:38:00 AM
From: DaiS  Respond to of 23519
 
Gene therapy

FWIW I can confirm that Vivus does continue to fund research on gene therapy of urologic cancers. So it is indeed not just gene therapy for ED.

I do not know further details yet but we can speculate that this might involve transurethral delivery and might relate to bladder and prostate cancer.

There is nothing to justify wild excitement but it does show that Vivus has broader horizons than many critics would have us believe.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News